Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06746519Phase 1Recruiting

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

Role: lead

NCT05177731Phase 3Active Not Recruiting

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Role: lead

NCT05557110Phase 2Completed

Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

Role: lead

NCT06250959Phase 2Recruiting

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Role: lead

NCT05675826Unknown

The Impact of Donor COVID-19 Infection Status on the Recipient in Allo-HSCT

Role: lead

NCT05466175Phase 2Unknown

A Study of Olverembatinib in the Treatment of Ph+ ALL

Role: lead

All 6 trials loaded